There have been no open-market insider trades at LB Pharmaceuticals Inc in the last 12 months.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 115 funds reported holding LBRX at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | Deep Track Capital, LP | 10% Owner | Buy | 2,000,000 | $15.00 | $30.0M | SEC |
| Sep 16, 2025 | Deep Track Capital, LP | 10% Owner | Buy | 666,666 | $15.00 | $10.0M | SEC |
| Sep 16, 2025 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Sep 16, 2025 | Nussbaum Ran | Director | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Sep 16, 2025 | Vida Ventures GP III, L.L.C. | 10% Owner | Buy | 332,566 | $15.00 | $5.0M | SEC |
| Sep 16, 2025 | Vida Ventures GP III, L.L.C. | 10% Owner | Buy | 767 | $15.00 | $12K | SEC |
There were no open-market insider trades in LBRX in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
115 investment managers reported holding LBRX in SEC Form 13F filings for Q2 2026.
No congressional trades in LBRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).